Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
ELVN-002 by Enliven Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ELVN-002 is under clinical development by Enliven Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...